GLG News by Psychiatrists

The news is important to show the benefits of using  SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), in treating persistent asthma in children 6 to 11 years old. This could be an added therapeutic intervention to asthma for young children, hence may lead to a relief sign for the sufferers....

Diabetes is one of most common disease suffered by millions around the world, yet treatment options are limited, and mainly confined with few oral medicines, insulin regulator bio-chemical treatment and other alternative medicines. The prospect of AEG33773, as an orally bioavailable small molecule...

The report is showing a market prospect for Ramelteon in Japan, thereby increasing the user numbers to benefit from insomnia from the use of Ramelteon. This drug showed no major abuse and dependence in the USA, however, it is not known if the clinical trials are to be carried...

Huntington's Disease is a tragic hereditary affliction often first manifesting in 30 and 40 year olds, with an autosomal dominant inheritance. Biotechnology is finally catching up with the disease to the extent that there is fundamental research (and drug discovery) underway that can render these offending...

The FDA has approved Abilify for Acute treatment of Manic and Mixed Bipolar I Episodes in 10 to 17 year olds.  The benefit to Otsuka and Bristol Myers will be quite significant in the market for several reasons.  The benefit to kids is more problematic.

The FDA’s approval of Abilify for treatment of acute manic and mixed episodes of pediatric Bipolar Disorder is a very important milestone.   Treatment with Abilify already has had growing off-label use in the pediatric population, in both acute and chronic settings, because of its favorable...

the key issue here is that there is a need for new medications for bipolar disorder which do not have weight gain. all the available atypicals, with the exception of ziprasidone cause significant weight gain. this agent is the only one not to hazardously affect weight.

A entirely new concept in curing incurable diseases, such as Huntington's Disease and MS is beginning to show Proof of Concept.  The next several years will witness an exponential rise in research in this arena, as biotechs such as Alnylam (ALNY) and ISIS (ISIS) demonstrate the feasibility of this...

It is only a matter of time, measured in months now, for the Apple Iphone to start treading on Blackberry's Turf.  There are many compelling reasons why this will be inevitable

OCD (Obsessive Compulsive Disorder) and SAD (Social Anxiety Disorder) are two of the more common...much more common than formerly thought...diagnoses and also two of the most difficult to treat.  JAZZ Pharmaceutical's new fluvoxamine formulation (Luvox CR) will invigorate patient self-identification...